Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

NCT01153763 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01153763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01153763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
August 9, 2010
Completion date
June 1, 2016
Enrollment
92 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma